Bavarian Nordic unveils key Phase 2 study results for BN-Brachyur
Category: #health  By Paroma Bhattacharya  Date: 2019-06-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bavarian Nordic unveils key Phase 2 study results for BN-Brachyur

Phase 2 trial was designed with the aim to observe combination of BN-Brachyury and radiation therapy in chordoma patients

Bavarian Nordic A/S, a Denmark-based biotechnology company, has recently announced that the Data and Safety Monitoring Board has confirmed a partial response in one of the first patients with chordoma enrolled and treated with the combination of radiation treatment and BN-Brachyury at the first evaluation timepoint.

This reportedly meets the initial pre-defined activity threshold for the first stage of the Phase 2 trial, due to which enrolment will be expanded to recruit another 19 patients, whereas the first 10 patients would continue to be treated and evaluated accordingly.

Apparently, the proof of concept of Phase 2 trial was designed with the aim to observe if combining the current standard of care, radiation therapy, with BN-Brachyury will result in a clinically meaningful objective response rate, which is measured as a percentage of patients with a reduction in tumor size within 12 months of radiation therapy. Under this timeframe, historical controls display an ORR of less than 5% with radiation alone.

Sources familiar with the matter mentioned that under the first stage of study, enrolment of 10 patients had been done between November 2018 and January 2019. After that, the study will now advance into stage 2, extending recruitment to a total of 29 patients with a goal of achieving objective responses in 4 patients, corresponding to a ~14% ORR for all patients recruited for the study to be considered a success.

According to President and Chief Executive Officer of Bavarian Nordic, Paul Chaplin, the company has shared the first Phase 2 data from its existing immuno-oncology pipeline, and also the first data signifying clinical activity of combining the company’s targeted immunotherapy with standard of care.

Chaplin added that the swift progression of this trial could possibly offer final results faster than expected and hopes this initial finding has confirmed in a greater number of patients, with BN-Brachyury expected to improve treatment options for patients with chordoma.

Source Credit: http://www.bavarian-nordic.com/investor/news/news.aspx?news=5645 



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Suning.com acquires Carrefour China for expanding FMCG operations
Suning.com acquires Carrefour China for expanding FMCG operations
By Paroma Bhattacharya

Suning.com, one of the largest non-government retailers in China, recently announced that it will buy an equity stake of 80% in Carrefour China, the local division of the biggest retailer in Europe, for 620 million Eur...

Shopify introduces AI-powered fulfillment network for SMB partners
Shopify introduces AI-powered fulfillment network for SMB partners
By Paroma Bhattacharya

Shopify, an e-commerce SaaS provider has reportedly introduced an AI powered fulfillment network for its merchants as the company is working to differentiate its product portfolio from other industry contenders.

<...

Pinterest unveils new partner program to boost shopping experiences
Pinterest unveils new partner program to boost shopping experiences
By Paroma Bhattacharya

Pinterest has reportedly rebranded its Pinterest Marketing Partners program into the global Pinterest Partner program, as it turns to third parties to introduce shopping experiences onto its platform.